EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement

Mahesh V Madhavan, Michael J Mack, Philippe Pibarot, Rebecca T Hahn, Raj Makkar, Vinod H Thourani, Susheel K Kodali, Samir R Kapadia, Philippe Genereux, Vasilis Babaliaros, Maria C Alu, Bradley Lubich und 3 weitere

JACC: Cardiovascular Interventions · 2026-07 · 19 (14) · 1944-1955

DOI: 10.1016/j.jcin.2026.05.023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-07. Verfasst von Mahesh V Madhavan und 14 weiteren Autor:innen. Beteiligte Einrichtung: NewYork-Presbyterian Hospital and the Weill Cornell Medicine, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Aortic Valve, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are limited studies comparing the impact of transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) by annular size. OBJECTIVES: The aim of this post hoc analysis from the PARTNER (Placement of Aortic Transcatheter Valves) 3 trial was to assess the relationship between annular size and outcomes among patients with severe aortic stenosis (AS) who underwent TAVR or SAVR. METHODS: Low-risk patients with severe, symptomatic AS were randomized to TAVR using the balloon-expandable SAPIEN 3 valve or SAVR. Patients were stratified by computed tomographic angiography-derived aortic annular area (small, ≤430 mm2; large, >430 mm2). The primary endpoint was the composite of death, stroke, or rehospitalization. Interactions among annular size, treatment strategy, and adjudicated 5-year clinical outcomes were assessed. RESULTS: Of the 925 patients with available computed tomographic angiography-derived annular size, 293 had small and 632 had large aortic annuli, respectively. Median follow-up duration was 5.2 years (Q1-Q3: 5.0-6.0 years). Five-year rates of the primary endpoint were similar for TAVR and SAVR in the overall cohort, results that were consistent for patients with small (21.2% vs 31.0%; OR: 0.60; 95% CI: 0.35-1.02) and large (23.5% vs 25.5%; OR: 0.90; 95% CI: 0.62-1.29) annuli, without effect modification by annular size (P for interaction = 0.22). Rates of bioprosthetic valve failure were similar and low at 5 years, without effect modification by annular size. Five-year health status was also similar between treatment modalities across annulus strata (P for interaction = 0.12). CONCLUSIONS: TAVR with the SAPIEN 3 valve led to similar 5-year clinical and health status outcomes compared with SAVR, irrespective of annular size. (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3]; NCT02675114).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisAortic ValveHeart Valve ProsthesisHeart Valve Prosthesis ImplantationTranscatheter Aortic Valve ReplacementHumansTreatment OutcomeTime FactorsRisk FactorsProsthesis DesignSeverity of Illness IndexMaleAged, 80 and overFemaleAgedComputed Tomography AngiographyPatient ReadmissionRisk AssessmentRecovery of FunctionStroke

Stichwörter der Autor:innen

aortic stenosisaortic valve replacementsmall annulustranscatheter aortic valve replacement

Autor:innen und Institutionen

  • NewYork-Presbyterian Hospital and the Weill Cornell Medicine, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
  • Baylor Scott & White Health, Plano, Texas, USA.
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
  • Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, USA.
  • Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia, USA.

Förderung

  • Edwards Lifesciences Corporation

Zitieren

APA

Madhavan, M. V., Mack, M. J., Pibarot, P., Hahn, R. T., Makkar, R., Thourani, V. H., Kodali, S. K., Kapadia, S. R., Genereux, P., Babaliaros, V., Alu, M. C., Lubich, B., Leon, M. B., Cohen, D. J., & PARTNER 3 Investigators (2026). Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement. JACC: Cardiovascular Interventions, 19(14), 1944-1955. https://doi.org/10.1016/j.jcin.2026.05.023

Vancouver

Madhavan MV, Mack MJ, Pibarot P, Hahn RT, Makkar R, Thourani VH, et al. Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2026;19(14):1944-1955. doi:10.1016/j.jcin.2026.05.023

BibTeX
@article{Madhavan2026,
  author = {Madhavan, Mahesh V and Mack, Michael J and Pibarot, Philippe and Hahn, Rebecca T and Makkar, Raj and Thourani, Vinod H and Kodali, Susheel K and Kapadia, Samir R and Genereux, Philippe and Babaliaros, Vasilis and Alu, Maria C and Lubich, Bradley and Leon, Martin B and Cohen, David J and PARTNER 3 Investigators, PARTNER 3 Investigators},
  title = {Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {14},
  pages = {1944--1955},
  doi = {10.1016/j.jcin.2026.05.023}
}
Kostenlos starten →